1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America and Europe Skin Cancer Diagnostics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America and Europe Skin Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America and Europe Skin Cancer Diagnostics Market Regional Analysis
6.2 North America and Europe Skin Cancer Diagnostics Market Revenue 2019-2028 (US$ Million)
6.3 North America and Europe Skin Cancer Diagnostics Market Forecast Analysis
7. North America and Europe Skin Cancer Diagnostics Market Analysis – by Type
7.1 Melanoma and Non-melanoma
- 7.1.1 Overview
- 7.1.2 Melanoma and Non-melanoma: North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. North America and Europe Skin Cancer Diagnostics Market Analysis – by Screening Type
8.1 Blood Tests
- 8.1.1 Overview
- 8.1.2 Blood Tests: North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Dermatoscopy
- 8.2.1 Overview
- 8.2.2 Dermatoscopy: North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Imaging Tests
- 8.3.1 Overview
- 8.3.2 Imaging Tests: North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.4 Lymph Node Biopsy
- 8.4.1 Overview
- 8.4.2 Lymph Node Biopsy: North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.5 Skin Biopsy
- 8.5.1 Overview
- 8.5.2 Skin Biopsy : North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. North America and Europe Skin Cancer Diagnostics Market – Europe Analysis
9.1 Overview
9.2 North America
- 9.2.1 North America and Europe Skin Cancer Diagnostics Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 9.2.1.1 North America and Europe Skin Cancer Diagnostics Market – Revenue and
Forecast Analysis – by Country
- 9.2.1.1 US:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.1.1 US: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.2.1.1.2 US: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.2.1.2 Canada:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.2.1 Canada: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.2.1.2.2 Canada: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.2.1.3 Mexico :
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.2.1.3.1 Mexico : North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.2.1.3.2 Mexico : North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
9.3 Europe
- 9.3.1 North America and Europe Skin Cancer Diagnostics Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 9.3.1.1 North America and Europe Skin Cancer Diagnostics Market – Revenue and
Forecast Analysis – by Country
- 9.3.1.1 UK:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.1.1 UK: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.1.2 UK: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.3.1.2 Germany:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.2.1 Germany: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.2.2 Germany: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.3.1.3 France:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.3.1 France: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.3.2 France: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.3.1.4 Russia:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.4.1 Russia: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.4.2 Russia: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.3.1.5 Italy:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.5.1 Italy: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.5.2 Italy: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
- 9.3.1.6 Rest of Europe:
North America and Europe Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.3.1.6.1 Rest of Europe: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Type
- 9.3.1.6.2 Rest of Europe: North America and Europe Skin Cancer Diagnostics Market Breakdown, by Screening Type
10. Competitive Landscape
10.1 Heat Map Analysis
10.2 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.3 Partnerships and Collaborations
11.4 Other Developments
12. Company Profiles
12.1 SkylineDx BV
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 AMLo Biosciences Limited
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 NeraCare GmbH
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 DermLite LLC
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 bioMerieux SA
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Veriskin Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Castle Biosciences, Inc.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 DermTech Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 HOFFMANN-LA ROCHE LTD.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Michelson Diagnostics Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
Get Free Sample For North America and Europe Skin Cancer Diagnostics Market
